共 292 条
[1]
Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[2]
Therasse P(2004)Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society Br J Cancer 90 2256-2260
[3]
Bogaerts J(2007)We should desist using RECIST, at least in GIST J Clin Oncol 25 1760-1764
[4]
Husband JE(2008)A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors J Clin Oncol 26 3550-2019
[5]
Schwartz LH(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2676
[6]
Spencer J(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-799
[7]
Benjamin RS(2005)Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792-598
[8]
Choi H(2006)Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies J Natl Cancer Inst 98 580-54
[9]
Macapinlac HA(2008)Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs Nat Clin Pract Oncol 5 44-262
[10]
Nathan P(2007)Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology 244 257-1628